ライフサイエンスコーパス: efavirenz

1 mary efficacy analysis (153 raltegravir, 154 efavirenz).

2 everse transcriptase inhibitors (nevirapine, efavirenz).

3 cellent compared with that of compound I and efavirenz.

4 ic tablets with lamivudine and nevirapine or efavirenz.

5 ransgenic mice chronically administered with efavirenz.

6 brentasvir may be significantly decreased by efavirenz.

7 ne, 128 (54%) to tenofovir, and 219 (92%) to efavirenz.

8 but not to the assignment of cabotegravir or efavirenz.

9 y 46%, consistent with induction of CYP3A by efavirenz.

10 suicidality compared with a regimen without efavirenz.

11 e/zidovudine plus lamivudine plus nevirapine/efavirenz.

12 vir is associated with more weight gain than efavirenz.

13 ne was associated with more weight gain than efavirenz.

14 cified plaque was negatively associated with efavirenz (0.7, 95% CI 0.57-0.97).

15 ssigned 268 mothers to dolutegravir (135) or efavirenz (133).

16 394 delivered on-study (200 raltegravir, 194 efavirenz); 307 were included in the primary efficacy an

17 In adjusted models, in utero exposure to efavirenz (4.7% exposed) was associated with increased r

18 The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiretroviral t

19 Of 28 subjects (14 and 14 on efavirenz 400 mg and 600 mg, respectively), CSF HIV RNA

20 misuse of the HIV antiretroviral medication efavirenz ((4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(tri

21 g once a day; each allocation was given with efavirenz 600 mg once a day and lamivudine 300 mg once a

22 30 mg once a day, 60 mg once a day, or oral efavirenz 600 mg once a day with dual nucleoside reverse

23 tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 600 mg) and achieving VS (<50 copies/mL).

24 l fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg.

25 g either raltegravir (400 mg twice daily) or efavirenz (600 mg each night) plus lamivudine 150 mg and

26 previr (240 mg twice daily) with and without efavirenz (600 mg once daily); or (3) faldaprevir (240 m

27 g) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovi

28 Efavirenz (600 mg/d) and stavudine plus lamivudine were

29 Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with

30 ravir or the reference treatment of low-dose efavirenz (a 400-mg dose, known as EFV400), combined wit

31 ighted through a synthesis of an analogue of efavirenz, a drug used for treating HIV.

32 roteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing pa

33 The anti-HIV drug efavirenz activates CYP46A1 at low drug levels while inh

34 Efavirenz affects the bioenergetics of neurons through a

35 avirenz plus antituberculosis drugs) and 50 (efavirenz alone) after initiation of antituberculosis tr

36 Efavirenz alters mitochondrial respiration, enhances rea

37 ricitabine was 2.35 (95% CI, 1.61-3.42) with efavirenz and 2.01 (95% CI, 1.36-2.98) with nevirapine.

38 z apparent clearance in patients taking both efavirenz and antituberculosis treatment was highly depe

39 panion pills because of interactions between efavirenz and bedaquiline.

40 d plasma and breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in human immun

41 2.90 (17 events) and 1.22 (5 events) in the efavirenz and efavirenz-free groups, respectively (hazar

42 with CYP2B6 and UGT1A1 genotypes that affect efavirenz and INSTI metabolism, respectively.

43 rienced participants with resistance to both efavirenz and lamivudine, 32 (35.6%) of whom were still

44 Mothers switched to efavirenz and maternal and infant plasma and breastmilk

45 The effects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depo

46 nnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir,

47 r cytotoxicity than the approved NNRTI drugs efavirenz and rilpivirine.

48 e mutation, does not prevent binding between efavirenz and RT-T/P but instead allows formation of a s

49 Cerebrospinal fluid (CSF) exposure of efavirenz and the metabolites 7-hydroxy (7OH) and 8-hydr

50 intake at weeks 2 and 6 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis

51 08 women were enrolled (206 raltegravir, 202 efavirenz) and 394 delivered on-study (200 raltegravir,

52 thers (30% in each group; 61 raltegravir, 59 efavirenz) and infants (25% in each group; 50 raltegravi

53 t-Naive, HIV-Infected Subjects of TMC278 and Efavirenz) and THRIVE (TMC278 Against HIV, in a Once-Dai

54 re 528, 280, and 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efaviren

55 re 580, 247, and 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efaviren

56 ly used antiretrovirals darunavir/ritonavir, efavirenz, and tenofovir to guide the coadministration o

57 Change in efavirenz apparent clearance in patients taking both efa

58 ow-acetylation NAT2 phenotype had the lowest efavirenz apparent clearance.

59 Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6

60 Efavirenz apparent oral clearance was estimated and the

61 Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR

62 intravaginal ring hormones are combined with efavirenz are warranted.

63 ilar in CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm (P = .836).

64 between CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm, suggesting th

65 In the efavirenz arm CYP2B6 metaboliser genotype was associated

66 pants in the dolutegravir arm and 168 in the efavirenz arm who consented to genotyping.

67 between CYP2B6 metabolizer genotypes in the efavirenz arm, and with the dolutegravir arm.

68 virenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.43; 90% CI, .42, .44 and nev

69 virenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.53; 90% CI, .50, .55 and nev

70 ngs support consideration of alternatives to efavirenz as part of first-line antiretroviral therapy f

71 Advantages of using efavirenz as part of treatment for children infected wit

72 fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at

73 7959 (0.04%) in which the mother was taking efavirenz at conception, 1 among 3840 (0.03%) in which t

74 commence antiretroviral regimens containing efavirenz at either 400 mg or 600 mg once daily.

75 tiretrovirals were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir.

76 immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).

77 ted with 12-month depression, but receipt of efavirenz-based antiretroviral therapy is not.

78 ed DMPA among HIV/TB co-infected women on an efavirenz-based antiretroviral treatment (ART) and rifam

79 sed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral treatment and rifampicin-

80 -infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (

81 r ART-naive (control group; n=25), receiving efavirenz-based ART (n=25), or receiving atazanavir-rito

82 s, between the lopinavir/ritonavir-based and efavirenz-based ART arms (7.4% vs 9.8%; P = .45).

83 though HIV-positive women using implants and efavirenz-based ART had a three-times higher risk of con

84 s and 3.3 per 100 person-years (1.8-4.8) for efavirenz-based ART users (adjusted incidence rate ratio

85 s and 5.4 per 100 person-years (4.0-6.8) for efavirenz-based ART users (adjusted IRR 1.2, 95% CI 0.91

86 arkedly reduced in participants who received efavirenz-based ART, accompanied by contraceptive failur

87 ts, with 1.6-2.8 higher rates in women using efavirenz-based ART.

88 gned to receive lopinavir/ritonavir-based or efavirenz-based ART.

89 ria or improve birth outcomes, compared with efavirenz-based ART.

90 associated with weight gain in PLWH starting efavirenz-based ART.

91 vaginal ring contraceptive was combined with efavirenz-based ART.

92 ide effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as fir

93 Raltegravir and efavirenz-based initial antiretroviral therapy have simi

94 <40 copies per mL) after at least 8 weeks of efavirenz-based or dolutegravir-based regimens were recr

95 use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral thera

96 as a combination of contraceptive method and efavirenz-based or nevirapine-based ART regimen.

97 An efavirenz-based regimen (with a 600-mg dose of efavirenz

98 8 and compared ART initiation policies of an efavirenz-based regimen in women intending pregnancy, an

99 a dolutegravir-based regimen rather than an efavirenz-based regimen, including in women intending pr

100 icipants were randomly assigned to switch to efavirenz-based therapy (n = 150) or continue ritonavir-

101 oosted lopinavir-based therapy, switching to efavirenz-based therapy compared with continuing ritonav

102 mised (1:1) to daily dolutegravir (50 mg) or efavirenz-based therapy.

103 omly assigned (1:1) to dolutegravir-based or efavirenz-based therapy.

104 Among studied drugs, Efavirenz, but not other NNRTIs, altered claudin-5 expre

105 s or treatment), though, reduced the rate of efavirenz clearance.

106 -dependant inhibitory effect of isoniazid on efavirenz clearance.

107 Median efavirenz Cmin during pregnancy was 1.35 microg/mL (inte

108 range [IQR], 0.90-2.07 microg/mL; 27% had an efavirenz Cmin of < 1 microg/mL), compared with a median

109 rog/mL (IQR, 1.40-3.59 microg/mL; 13% had an efavirenz Cmin of < 1 microg/mL).

110 women with extensive CYP2B6 genotypes had an efavirenz Cmin of <1 microg/mL.

111 Rifampin did not reduce the efavirenz Cmin.

112 enofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir diso

113 ss-resistance to etravirine, nevirapine, and efavirenz compared with wild type HIV-1 plasma-derived c

114 Efavirenz concentration in CSF was >0.51 ng/mL (proposed

115 or wild-type virus) in all subjects, and 8OH-efavirenz concentration in CSF was >3.3 ng/mL (a propose

116 mean ratio, 0.56 [90% CI, .42-.74]), CSF 8OH-efavirenz concentration was not (P = .242 for associatio

117 Whereas CSF efavirenz concentration was significantly associated wit

118 ocytes were treated with clinically relevant efavirenz concentration.

119 proportion of participants with midinterval efavirenz concentrations >/=1 mg/L did not cross below t

120 Numbers of participants with efavirenz concentrations >/=1 mg/L were 85 (98%) at week

121 Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with 90% confidence intervals

122 s were each associated with increased plasma efavirenz concentrations during antituberculosis therapy

123 2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk

124 ithdrawal of the inhibitory effect of higher efavirenz concentrations on weight gain.

125 Pregnancy increased the risk of low efavirenz concentrations, but MTCT was rare.

126 ion polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would im

127 y, participants were randomly assigned to an efavirenz-containing (n = 3241) or efavirenz-free (n = 2

128 Initial treatment with an efavirenz-containing antiretroviral regimen was associat

129 participants who were randomized to receive efavirenz-containing regimens in AIDS Clinical Trials Gr

130 switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine

131 mly assigned treatment-naive participants to efavirenz-containing regimens; suicidality was defined a

132 r superior to first-line regimens containing efavirenz, darunavir/ritonavir, or raltegravir regardles

133 Efavirenz decreased faldaprevir area under the concentra

134 At the same time, efavirenz diminished autophagic activity, a surprising r

135 D risks may be higher with dolutegravir than efavirenz, dolutegravir will lead to many fewer deaths a

136 The estimated maximum infant efavirenz dose from breast milk was 809 microg/kg/day (2

137 s of further experiments, we identified that efavirenz dysregulated ER stress and autophagy by blocki

138 anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in culture

139 dolutegravir, and elvitegravir/cobicstat) or efavirenz (EFV) as an active comparator, between 2009 an

140 Previously, we found that the anti-HIV drug efavirenz (EFV) can pharmacologically activate CYP46A1 i

141 nal cells from the excitotoxic insult, while efavirenz (EFV) did not contrast the neurotoxic effect o

142 cacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials: DRIVE-FORWA

143 nses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in initial antiretroviral regimens among

144 plus ritonavir (DRV+r) in DRIVE-FORWARD and efavirenz (EFV) in P007 and DRIVE-AHEAD.

145 Efavirenz (EFV) is an anti-HIV drug, and cytochrome P450

146 current study was conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based co

147 Compared with no ART, efavirenz (EFV) reduced exposure to all antimalarial com

148 side reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) showed subunit-specific perturbation in

149 We compared the effect of switching efavirenz (EFV) to raltegravir (RAL) on hepatic steatosi

150 onstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lo

151 The distribution of efavirenz (EFV) was then monitored in a series of hair s

152 In the presence of efavirenz (EFV), a virus carrying RT-K103N together with

153 Efavirenz (EFV), a widely used antiretroviral drug, is a

154 We found that four pharmaceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galanta

155 were randomised 1:1 to dolutegravir (DTG) or efavirenz (EFV)-containing ART until 2 weeks post-partum

156 erculosis therapy, then 50 mg once daily) or efavirenz (EFV; 600 mg daily) with 2 nucleoside reverse

157 nts from the ADVANCE study randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (

158 mtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumar

159 imen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumar

160 suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumar

161 events compared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumar

162 bine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate)

163 proxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (E

164 tigates the BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

165 darunavir/ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

166 etic analogs and hydroxylated metabolites of efavirenz enhance CYP46A1 activity, with reduced unwante

167 ide reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on th

168 uicidality and genotypes that predict plasma efavirenz exposure among AIDS Clinical Trials Group stud

169 Importantly, Efavirenz exposure increased the severity of stroke in a

170 Genotypes that predict higher plasma efavirenz exposure were associated with increased risk o

171 Genotypes that predict plasma efavirenz exposure were defined by CYP2B6 and CYP2A6 pol

172 pants who were pretreated with rifampicin or efavirenz followed by RTV-containing regimens.

173 that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

174 that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

175 ived 50 mg of daily dolutegravir in place of efavirenz for 8 weeks, then began once-weekly rifapentin

176 Dolutegravir is superior to efavirenz for HIV antiretroviral therapy (ART) but may b

177 l countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (

178 ned to an efavirenz-containing (n = 3241) or efavirenz-free (n = 2091) regimen.

179 efavirenz group and 3.66 (15 events) in the efavirenz-free group (hazard ratio, 2.28 [95% CI, 1.27 t

180 suicides in the efavirenz group and 1 in the efavirenz-free group were reported.

181 ts) and 1.22 (5 events) in the efavirenz and efavirenz-free groups, respectively (hazard ratio, 2.58

182 Efavirenz versus efavirenz-free regimens.

183 .001) and cytochrome P450 2B6 genotype (CSF efavirenz GG to GT/TT geometric mean ratio, 0.56 [90% CI

184 as not (P = .242 for association and CSF 8OH-efavirenz GG to GT/TT geometric mean ratio, 1.52 [90% CI

185 events compared with 14 (11%) of 131 in the efavirenz group (p=0.013), particularly surrounding preg

186 per mL, compared with 50 (43%) of 117 in the efavirenz group (risk ratio 1.64, 95% CI 1.31-2.06).

187 s of viral failure were 0.027 (n = 4) in the efavirenz group and 0.020 (n = 3) in the ritonavir-boost

188 ebound by 48 weeks was 0.176 (n = 26) in the efavirenz group and 0.284 (n = 42) in the ritonavir-boos

189 Eight suicides in the efavirenz group and 1 in the efavirenz-free group were r

190 000 person-years was 8.08 (47 events) in the efavirenz group and 3.66 (15 events) in the efavirenz-fr

191 hree pregnancies (3/20, 15%) occurred in the efavirenz group between weeks 36 and 48.

192 ovir disoproxil fumarate, emtricitabine, and efavirenz group discontinued due to treatment-related ad

193 ovir disoproxil fumarate, emtricitabine, and efavirenz group had achieved a plasma HIV-1 RNA concentr

194 ups, respectively) and 46 (74%) of 62 in the efavirenz group had fewer than 50 copies per mL of HIV-1

195 n the raltegravir group and 129 (84%) in the efavirenz group met the primary efficacy outcome (absolu

196 as 2.88% (95% CI, 1.26%-4.49%) higher in the efavirenz group than in the ritonavir-boosted lopinavir

197 ths in the dolutegravir group and one in the efavirenz group were considered unrelated to treatment.

198 respectively) versus 44 (71%; 60-82) in the efavirenz group were virologically suppressed at week 48

199 respectively) versus 39 (63%; 51-75) in the efavirenz group were virologically suppressed at week 96

200 s (125 in the dolutegravir group, 125 in the efavirenz group) and their infants in efficacy analyses,

201 ovir disoproxil fumarate, emtricitabine, and efavirenz group), and was greater among women than men.

202 endpoint: 25 in the control group, 25 in the efavirenz group, and 24 in the atazanavir group.

203 verse events compared with nine (15%) in the efavirenz group.

204 ovir disoproxil fumarate, emtricitabine, and efavirenz group.

205 ntravaginal ring use, participants receiving efavirenz had 79% lower etonogestrel (GMR 0.21, 90% CI 0

206 ceiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline an

207 e-daily darunavir, once-daily darunavir, and efavirenz had the highest CSF 95% inhibitory quotients (

208 iral therapy (ART) with either nevirapine or efavirenz have suggested poorer virological outcomes in

209 ion pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunode

210 rns about possible reduced viral efficacy of efavirenz in children exposed to nevirapine for preventi

211 etroviral therapy with either raltegravir or efavirenz in late pregnancy.

212 restricted to the choice of dolutegravir or efavirenz in new ART initiators.

213 prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a treatment-as-p

214 ranscriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa.

215 ricitabine, lamivudine, and indinavir), only efavirenz increased ER stress via upregulation and activ

216 Similar to LSD, efavirenz induces head-twitch responses in wild-type, bu

217 mples were obtained a mean of 14 hours after efavirenz intake at weeks 2 and 6 after initiation of ef

218 The main side effects attributed to efavirenz involve the CNS, but the underlying mechanisms

219 CAC score >0 was negatively associated with efavirenz (IPTW adjusted odds ratio per 5 years 0.73, 95

220 We rejected the null hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (P

221 ir and use of boosted protease inhibitors or efavirenz is not recommended.

222 The antiretroviral drug efavirenz is widely used during breastfeeding.

223 avirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organiz

224 Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly

225 One of these-efavirenz, lamivudine, and zidovudine-was the second mos

226 without clinically meaningful reductions in efavirenz mid-dosing concentrations or virologic suppres

227 t-line antiretroviral (ARV) drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside r

228 on lack-of-prophylactic efficacy, darunavir, efavirenz, nevirapine, etravirine and rilpivirine could

229 ot observed in control subjects treated with efavirenz nor with a lower dose of 100 mg cenicriviroc.

230 ed weight gain on dolutegravir compared with efavirenz observed in ADVANCE and other studies.

231 Here we identified this allosteric site for efavirenz on CYP46A1 by using a combination of hydrogen-

232 e effect of the integrase inhibitor EVG over efavirenz on immune activation, which may affect vascula

233 The AUC(0-8 h) of efavirenz or atazanavir did not differ between the group

234 nnucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine) or a boosted protease inhibito

235 ed to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of c

236 As secondary outcomes, efavirenz or ritonavir-boosted atazanavir concentrations

237 We hypothesised that ART containing either efavirenz or ritonavir-boosted atazanavir would alter pl

238 inhibition can contribute to the toxicity of efavirenz or the development of neurodegenerative diseas

239 We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (A

240 2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breas

241 rculosis treatment or prophylaxis can affect efavirenz pharmacokinetics, maternal human immunodeficie

242 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis drugs) and 50 (efavirenz

243 irine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96.

244 ose plus oral rilpivirine 25 mg or continued efavirenz plus NRTIs for an additional 72 weeks.

245 previr (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN/RBV for 12 weeks and peg-IFN/RBV

246 xed-dose combination tenofovir/emtricitabine/efavirenz, presence of both nonnucleoside reverse transc

247 Further, efavirenz promotes formation of the E138-K101 salt bridg

248 Compared with efavirenz, protease inhibitors were associated with high

249 veness under a policy of ART initiation with efavirenz- rather than dolutegravir-based regimens due t

250 Concerns have been raised about efavirenz reducing the effectiveness of contraceptive im

251 combination of tenofovir, emtricitabine, and efavirenz) regardless of CD4 cell count (intervention) o

252 egravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine a

253 lass PDR to a mainly tenofovir/emtricitabine/efavirenz regimen was associated with poorer VS.

254 No efavirenz related toxicity was reported.

255 One patient developed new efavirenz resistance after reinitiation of antiretrovira

256 randomized to the 400 mg and 600 mg doses of efavirenz, respectively.

257 regimen of tenofovir and emtricitabine with efavirenz, rilpivirine, or raltegravir.

258 he local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group).

259 With both doses of efavirenz studied, CSF concentrations were considered ad

260 ovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared w

261 r with antiretroviral therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitab

262 Among studied drugs (efavirenz, tenofovir, emtricitabine, lamivudine, and ind

263 re at week 48 compared to emtricitabine with efavirenz/tenofovir (10.8% vs 3.6%; adjusted odds ratio

264 ) initiated lamivudine or emtricitabine with efavirenz/tenofovir or nevirapine/tenofovir.

265 children exposed to combination regimens of efavirenz that included zidovudine plus lamivudine than

266 ly by some marketed drugs, as exemplified by efavirenz, the anti-HIV medication.

267 creased plasma clearance over compound I and efavirenz, the standard of care NNRTI.

268 Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was m

269 posure was observed when coadministered with efavirenz; this decrease can be managed using the higher

270 ould increase when given with rifampicin and efavirenz, thus increasing risk of ovulation.

271 e a platform for structural modifications of efavirenz to modulate CYP46A1 activity as a therapeutic

272 ansition from first-line regimens containing efavirenz to regimens containing dolutegravir formulatio

273 eight gain at 48 weeks following switch from efavirenz- to INSTI-based regimens among patients who ha

274 enetics of weight gain following switch from efavirenz- to INSTI-based regimens.

275 Among patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was a

276 and 60 mg groups, respectively) and 42 (68%) efavirenz-treated patients.

277 YP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.

278 Against HIV, in a Once-Daily Regimen Versus Efavirenz) trials.

279 Efavirenz trough concentrations (Cmin) were predicted us

280 The relationship between efavirenz use and suicidality is not well-defined.

281 ticipants (2:1; blocks of six, stratified by efavirenz use at screening) to switch to coformulated el

282 Efavirenz versus efavirenz-free regimens.

283 < 0.001; OR = 17.6 [3.26-95.3], P < 0.0001); efavirenz was associated with nonspecific hepatitis or s

284 CSF exposure of 8OH-efavirenz was not dependent on plasma exposure and, as w

285 Efavirenz was open-label in 3 of 4 studies.

286 DMPA, when given with rifampicin and efavirenz, was safe.

287 abolites 7-hydroxy (7OH) and 8-hydroxy (8OH) efavirenz were assessed after at least 12 weeks of thera

288 neuroinflammatory disorders, the effects of efavirenz were evaluated in the presence of exogenous ni

289 replication, although concentrations of 8OH-efavirenz were greater than those reportedly associated

290 escribed NNRTI-based ART, participants given efavirenz were less likely to have virological failure t

291 que, while tenofovir disoproxil fumarate and efavirenz were negatively associated with any plaque and

292 concentrations (lamivudine, nevirapine, and efavirenz) were measured on stored samples preswitch.

293 y and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy.

294 giving birth with dolutegravir compared with efavirenz, when initiated during the third trimester.

295 with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs were associate

296 l fumarate (p=0.001) but not those receiving efavirenz with abacavir (p=0.65).

297 We studied the interaction of efavirenz with daily rifapentine and isoniazid in human

298 gain at week 48 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) b

299 fants (25% in each group; 50 raltegravir, 48 efavirenz), with no treatment-related deaths.

300 ne plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in ef